NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, October 25th. Investors of record on Wednesday, November 13th will be paid a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.59%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its board has initiated a share repurchase plan on Tuesday, January 29th 2019, which authorizes the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 4.1% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

Allergan plc (NYSE:AGN) posted its quarterly earnings results on Tuesday, November, 5th. The company reported $4.25 earnings per share for the quarter, meeting the consensus estimate of $4.25. The business had revenue of $4.03 billion for the quarter, compared to analysts' expectations of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. Allergan's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $4.25 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 Wall Street analysts have issued twelve-month price objectives for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's share price to reach $175.90 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Press coverage about AGN stock has trended positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 11,450,000 shares, an increase of 10.8% from the September 15th total of 10,330,000 shares. Based on an average daily volume of 3,220,000 shares, the short-interest ratio is currently 3.6 days. Currently, 3.5% of the company's stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (4.51%), Third Point LLC (1.10%), Assenagon Asset Management S.A. (0.54%), Boussard & Gavaudan Investment Management LLP (0.40%), Sachem Head Capital Management LP (0.39%) and Newport Trust Co (0.38%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Russell Investments Group Ltd., Great West Life Assurance Co. Can, California State Teachers Retirement System and Envestnet Asset Management Inc.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Third Point LLC, State Street Corp, Assenagon Asset Management S.A., Boussard & Gavaudan Investment Management LLP, Sachem Head Capital Management LP, Canyon Capital Advisors LLC, York Capital Management Global Advisors LLC and Tibra Equities Europe Ltd. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $186.37.

Allergan has a market capitalization of $61.18 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]